YCBD Stock Overview Produces and distributes various cannabidiol (CBD) products in the United States. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for cbdMD Historical stock prices Current Share Price US$0.57 52 Week High US$1.34 52 Week Low US$0.31 Beta 2.04 1 Month Change -0.95% 3 Month Change 24.35% 1 Year Change -23.01% 3 Year Change -98.70% 5 Year Change -98.88% Change since IPO -99.56%
Recent News & Updates
New major risk - Share price stability Jan 03
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Dec 19
New major risk - Shareholder dilution Nov 29
cbdMD, Inc. Announces Acceptance of Compliance Plan by NYSE American Aug 28
Consensus EPS estimates upgraded to US$2.63 loss Aug 21
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 16 See more updates
New major risk - Share price stability Jan 03
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Dec 19
New major risk - Shareholder dilution Nov 29
cbdMD, Inc. Announces Acceptance of Compliance Plan by NYSE American Aug 28
Consensus EPS estimates upgraded to US$2.63 loss Aug 21
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 16 cbdMD Receives Non-Compliance Letter from NYSE American Regarding Shareholders Equity Jun 10
Consensus revenue estimates fall by 12% May 22
Second quarter 2024 earnings: EPS and revenues miss analyst expectations May 17
cbdMD, Inc., Annual General Meeting, Mar 29, 2024 Feb 15
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 14
Full year 2023 earnings: EPS and revenues miss analyst expectations Dec 24
No longer forecast to breakeven Dec 24
New major risk - Share price stability Nov 01
Third quarter 2023 earnings released: US$1.16 loss per share (vs US$24.76 loss in 3Q 2022) Aug 11
Second quarter 2023 earnings released: US$1.74 loss per share (vs US$4.32 loss in 2Q 2022) May 17
First quarter 2023 earnings released: US$0.082 loss per share (vs US$0.35 loss in 1Q 2022) Feb 15
cbdMD Appoints Shannon Charles as Chief Marketing Officer Jan 13
cbdMD, Inc., Annual General Meeting, Feb 16, 2023 Jan 05
Full year 2022 earnings released: US$1.24 loss per share (vs US$0.47 loss in FY 2021) Dec 16
Insufficient new directors Nov 16
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 12 cbdMD, Inc. Announces Resignation of Martin Sumichrast as CEO
cbdMD, Inc. Announces Board Changes Jun 05
Insufficient new directors Jun 01 cbdMD, Inc. Announces Resignation of Scott Coffman as Co-Chief Executive Officer
Second quarter 2022 earnings: EPS and revenues miss analyst expectations May 14
Insufficient new directors May 02
cbdMD Requests the Food and Drug Administration (FDA) Remove the Drug Exclusion for CBD and Review cbdMD’s Extensive Safety Submission Feb 24
cbdMD Becomes First American CBD Brand to Receive Validation by the United Kingdom Food Standards Agency Feb 18
cbdMD, Inc. Becomes the First CBD Company to Earn NSF International’s Certified for Sport Certification Feb 08
cbdMD, Inc., Annual General Meeting, Mar 11, 2022 Jan 28
cbdMD, Inc. Withdraws Revenue Guidance for the Quarter Ending December 31, 2021 Dec 19
cbdMD, Inc. Launches New Full Spectrum Product Line Sep 29
cbdMD, Inc. Revises Sales Guidance for the First Quarter of Fiscal 2022 Aug 15
Third quarter 2021 earnings released: EPS US$0.017 (vs US$0.18 loss in 3Q 2020) Aug 13
Consensus EPS estimates fall to -US$0.45 Jun 20
Second quarter 2021 earnings released: US$0.24 loss per share (vs US$0.41 profit in 2Q 2020) May 13
cbdMD, Inc. Provides Net Sales Guidance for the First Quarter of Fiscal 2022 May 13
cbdMD (NYSEMKT:YCBD) Has Debt But No Earnings; Should You Worry? Mar 23 cbdMD, Inc. Elects Sim Farar as Director
Chairman & Co-CEO recently sold US$240k worth of stock Mar 14
cbdMD, Inc. Announces Order by Court Staying California Litigation Mar 09
Independent Director recently sold US$81k worth of stock Mar 09
cbdMD, Inc. Appoints T. Ronan Kennedy to Serve as Chief Operating Officer Mar 06
Independent Director notifies of intention to sell stock Mar 05
Chairman & Co-CEO recently sold US$1.8m worth of stock Feb 23
This Insider Has Just Sold Shares In cbdMD, Inc. (NYSEMKT:YCBD) Feb 23
Chairman & Co-CEO notifies of intention to sell stock Feb 21
Price target raised to US$6.03 Feb 14
First quarter 2021 earnings released: US$0.18 loss per share (vs US$0.47 profit in 1Q 2020) Feb 11
Revenue and earnings beat expectations Feb 11
Analysts update estimates Feb 10
If You Had Bought cbdMD (NYSEMKT:YCBD) Stock A Year Ago, You Could Pocket A 383% Gain Today Feb 09
Investor sentiment improved over the past week Feb 04
New 90-day high: US$4.14 Feb 03
Price target raised to US$5.77 Jan 31
cbdMD, Inc., Annual General Meeting, Mar 12, 2021 Jan 26
We Wouldn't Rely On cbdMD's (NYSEMKT:YCBD) Statutory Earnings As A Guide Jan 13
New 90-day high: US$3.40 Jan 13
Investor sentiment improved over the past week Jan 12
cbdMD Enters Global Beauty and Skincare Market With Launch of “cbdMD Botanicals” Jan 09
Price target raised to US$5.53 Dec 30
Revenue beats expectations, earnings disappoint Dec 24
Full year 2020 earnings released: EPS US$0.28 Dec 24
New 90-day high: US$3.36 Dec 24
Is cbdMD (NYSEMKT:YCBD) Using Debt Sensibly? Dec 15
New 90-day high: US$3.01 Dec 01
Market bids up stock over the past week Nov 06
New 90-day low: US$1.84 Oct 07
Pro Group, Inc. Selects cbdMD and Paw CBD as Exclusive Distributor of CBD Brands Oct 03 cbdMD, Inc Announces Resignation of Mark Elliott as Chief Operating Officer, effective October 01, 2020
Price target raised to US$4.87 Aug 19
Analysts increase EPS estimates to US$0.72 Aug 19
cbdMD, Inc.(AMEX:YCBD) dropped from Russell Small Cap Completeness Index Jul 03 cbdMD, Inc.(AMEX:YCBD) dropped from Russell Microcap Value Index Shareholder Returns YCBD US Pharmaceuticals US Market 7D -3.1% 2.3% -0.9% 1Y -23.0% 4.3% 22.6%
See full shareholder returns
Return vs Market: YCBD underperformed the US Market which returned 22.6% over the past year.
Price Volatility Is YCBD's price volatile compared to industry and market? YCBD volatility YCBD Average Weekly Movement 21.2% Pharmaceuticals Industry Average Movement 10.4% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.2%
Stable Share Price: YCBD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: YCBD's weekly volatility has increased from 14% to 21% over the past year.
About the Company cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, ready to drink cans, and sleep, focus, and calming aids.
Show more cbdMD, Inc. Fundamentals Summary How do cbdMD's earnings and revenue compare to its market cap? YCBD fundamental statistics Market cap US$3.17m Earnings (TTM ) -US$7.70m Revenue (TTM ) US$19.48m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) YCBD income statement (TTM ) Revenue US$19.48m Cost of Revenue US$7.49m Gross Profit US$12.00m Other Expenses US$19.70m Earnings -US$7.70m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.39 Gross Margin 61.57% Net Profit Margin -39.54% Debt/Equity Ratio 59.7%
How did YCBD perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/02 01:39 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources cbdMD, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Hickey Benchmark Company William Sutherland Benchmark Company Pablo Zuanic Cantor Fitzgerald & Co.
Show 1 more analysts 
